Dr. Yozo Nakazawa, a pediatric oncologist at Shinshu University, is spearheading Japan's first clinical trials using non-viral CAR-T therapy for rare and treatment-resistant leukemias such as AML and JMML.

Inspired during his postdoctoral research at Baylor College of Medicine, Nakazawa sought a scalable, low-cost alternative to viral-vector CAR-Ts. His team leveraged the PiggyBac transposon system and electroporation to create T cells with stem-like memory — enabling safer, longer-lasting cancer immunotherapies.

In 2020, he co-founded A-SEEDS, now conducting multi-national trials in Japan, the U.S., and Australia. The company aims to bring CAR-T to rare cancers overlooked by major pharma — with a lean, Japan-style approach.

???? A unique playbook for Asia's cell therapy ecosystem — built on precision, affordability, and global reach.
Read more: https://bit.ly/v117viewpoint

Follow #Globalbio for more eye-opening news of biotechnology! 

#CellTherapy #CAR_T #Immunotherapy #NonViralVector #BiotechInnovation #JapanBiotech #A_SEEDS #RareCancers #GMPManufacturing #TransposonTechnology #RegenerativeMedicine #LinkedInBiotech